Want to see UCBJY full AI Analyst Report?
UCBJY Stock Chart & Stats
$129.21
$0.98(0.71%)
At close: 4:00 PM EDT
$129.21
$0.98(0.71%)
Day’s Range― - ―
52-Week Range$114.72 - $168.70
Previous CloseN/A
Volume40.38K
Average Volume (3M)2.85K
Market Cap
$47.68B
Enterprise Value$61.29K
Total Cash (Recent Filing)$796.67M
Total Debt (Recent Filing)$3.59B
Price to Earnings (P/E)18.7
Beta0.39
Next Earnings
Feb 25, 2027EPS Estimate
3.01Next Dividend Ex-DateN/A
Dividend Yield0.68%
Share Statistics
EPS (TTM)5.81
Shares Outstanding389,011,320
10 Day Avg. Volume1,843
30 Day Avg. Volume2,850
Financial Highlights & Ratios
PEG Ratio0.76
Price to Book (P/B)4.16
Price to Sales (P/S)6.08
P/FCF Ratio25.02
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)6.65
Revenue Forecast (FY)$10.02B
Bulls Say, Bears Say
Bulls Say
BIMZELX Growth And Commercial MomentumRapid BIMZELX adoption across psoriasis, rheumatology and HS provides a scalable growth engine. Broad approvals, expanding patient use and higher peak-sales expectations can support durable revenue growth and offset mature brands.
Strong Growth, Margins And Upgraded GuidanceThe combination of strong sales growth, 40.7% H1 EBITDA margin and upgraded guidance indicates effective commercial execution and operating leverage. Sustained performance would strengthen earnings capacity and fund continued investment.
Improving Cash Generation And Financial FlexibilityStronger free cash flow and a meaningful equity base improve UCB’s ability to finance R&D, acquisitions and shareholder commitments. Debt reduction also provides resilience, although cash conversion has varied across prior years.
Bears Say
BRIVIACT Loss Of ExclusivityGeneric competition creates a substantial, visible erosion risk for an established neurology product. The expected decline can weigh on portfolio stability and require successful launches and pipeline assets to replace lost cash flows.
Net Pricing Pressure On BIMZELXBroader access may improve long-term patient reach, but lower net pricing can constrain BIMZELX revenue quality and margins. The risk is amplified because management did not provide product-level pricing guidance.
Acquisition-related Debt And Integration CostsAcquisitions may expand UCB’s pipeline, but higher leverage, interest expense and integration spending can reduce financial flexibility and dilute near-term operating leverage. Returns depend on successful development and commercial execution.
UCB SA News
UCBJY FAQ
What was UCB SA’s price range in the past 12 months?
UCB SA lowest stock price was $114.72 and its highest was $168.70 in the past 12 months.
What is UCB SA’s market cap?
UCB SA’s market cap is $47.68B.
When is UCB SA’s upcoming earnings report date?
UCB SA’s upcoming earnings report date is Feb 25, 2027 which is in 178 days.
How were UCB SA’s earnings last quarter?
UCB SA released its earnings results on Jul 30, 2026. The company reported $3.934 earnings per share for the quarter, beating the consensus estimate of $2.909 by $1.025.
Is UCB SA overvalued?
According to Wall Street analysts UCB SA’s price is currently Overvalued.
Does UCB SA pay dividends?
UCB SA pays a Annually dividend of $0.85 which represents an annual dividend yield of 0.68%. See more information on UCB SA dividends here
What is UCB SA’s EPS estimate?
UCB SA’s EPS estimate is 3.01.
How many shares outstanding does UCB SA have?
UCB SA has 389,011,320 shares outstanding.
What happened to UCB SA’s price movement after its last earnings report?
UCB SA reported an EPS of $3.934 in its last earnings report, beating expectations of $2.909. Following the earnings report the stock price went down -12.584%.
Which hedge fund is a major shareholder of UCB SA?
Currently, no hedge funds are holding shares in UCBJY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
UCB SA Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
57.69%
12-Months-Change
Fundamentals
Return on Equity
0.68%
Trailing 12-Months
Asset Growth
16.93%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
UCB SA
UCB S.A. is a biopharmaceutical enterprise dedicated to developing innovative treatments and solutions for individuals living with neurological and immunological diseases. Its primary product, Cimzia, addresses a spectrum of inflammatory TNF-mediated conditions, encompassing ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis. For epilepsy management, the company provides Vimpat, Keppra, and Briviact, alongside Nayzilam, an emergency nasal spray for seizure clusters. Neupro is offered for Parkinson's disease and restless legs syndrome, while Zyrtec and Xyzal alleviate allergy symptoms. The portfolio further extends to Evenity, a treatment for osteoporosis in postmenopausal women, and BIMZELX, used for psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa. Dapirolizumab pegol is also available for systemic lupus erythematosus. UCB maintains a robust development pipeline featuring therapies such as rozanolixizumab for myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan for myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam for stereotypic prolonged seizures; Bepranemab for Alzheimer's disease; and UCB0599 for Parkinson's disease. Additionally, the company engages in contract manufacturing services. UCB S.A. has forged collaborative agreements with partners including Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. Its operational presence spans the United States, Japan, Germany, a broader European footprint (including Spain, France, Italy, the United Kingdom, and Ireland), China, Belgium, and other global territories. Incorporated in 1925, the company's headquarters are situated in Brussels, Belgium.
UCBJY Company Deck
UCBJY Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a strongly positive operational and financial performance in H1 2026: robust top-line growth, expanding margins and EBITDA, upgraded guidance, and clear commercial momentum for key growth drivers (notably BIMZELX) alongside meaningful pipeline and strategic acquisitions positioning the company for sustained longer-term growth. Notable risks include BRIVIACT loss of exclusivity with large expected sales declines, anticipated net price pressure from recent access wins (near-term H2 price erosion before volume benefits), increased G&A and integration costs from acquisitions, and competition/heterogeneity risks in HS. On balance, the positive execution, upgraded guidance and attractive pipeline developments outweigh the near-term headwinds.View all UCBJY earnings summariesTechnical Analysis
Ownership Overview
―
Insiders
<0.01% Mutual Funds
<0.01% Other Institutional Investors
99.99% Public Companies and
Individual Investors